Items where authors include "Devuyst, O."

Article

Devuyst, O. orcid.org/0000-0003-3744-4767, Ahn, C., Barten, T.R.M. et al. (24 more authors) (2025) KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney International, 107 (2). S1-S239. ISSN 0085-2538

Torres, V.E., Ahn, C., Barten, T.R.M. et al. (27 more authors) (2025) KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary. Kidney International, 107 (2). pp. 234-254. ISSN 0085-2538

Zagorec, N., Calamel, A., Delaporte, M. et al. (24 more authors) (2024) Clinical spectrum and prognosis of atypical autosomal dominant polycystic kidney disease caused by monoallelic pathogenic variants of IFT140. American Journal of Kidney Diseases. ISSN 0272-6386

Fung, W.W.-S. orcid.org/0000-0001-7676-7628, Szeto, C.-C. orcid.org/0000-0002-8898-8505, Chow, K.-M. orcid.org/0000-0001-5310-5197 et al. (8 more authors) (2024) Clinical characteristics and kidney outcomes in Chinese patients with autosomal dominant polycystic kidney disease. Kidney360, 5 (5). pp. 715-723. ISSN 2641-7650

Taylor, J., Thomas, R., Metherall, P. et al. (15 more authors) (2024) An artificial intelligence generated automated algorithm to measure total kidney volume in ADPKD. Kidney International Reports, 9 (2). pp. 249-256. ISSN 2468-0249

Winterbottom, J., Simms, R.J., Caroli, A. et al. (10 more authors) (2022) Flank pain has a significant adverse impact on quality of life in ADPKD: the CYSTic-QoL study. Clinical Kidney Journal, 15 (11). pp. 2063-2071. ISSN 2048-8505

Müller, R.-U., Lianne Messchendorp, A., Birn, H. et al. (20 more authors) (2022) An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International. Kidneys, 11 (1). pp. 37-39. ISSN 2307-1257

Müller, R.-U., Messchendorp, A.L., Birn, H. et al. (20 more authors) (2022) An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International. Nephrology Dialysis Transplantation, 37 (5). pp. 825-839. ISSN 0931-0509

Harris, T., Sandford, R., de Coninck, B. et al. (17 more authors) (2018) European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care: European ADPKD Forum and Multispecialist Roundtable participants. Nephrology Dialysis Transplantation, 33 (4). pp. 563-573. ISSN 0931-0509

Gansevoort, R.T., Arici, M., Benzing, T. et al. (18 more authors) (2016) Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrology Dialysis Transplantation, 31 (3). pp. 337-348. ISSN 0931-0509

Proceedings Paper

Winterbottom, J., Simms, R., Caroli, A. et al. (10 more authors) (2021) MO023: Flank pain has a major negative impact on health-related quality of life in ADPKD: The CYSTic I Study. In: Nephrology Dialysis Transplantation. 58th ERA-EDTA Congress, 05-08 Jun 2021, Berlin, Germany. Oxford University Press , i102.